BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31480372)

  • 1. Ultra-Mutation in
    Barresi V; Simbolo M; Mafficini A; Piredda ML; Caffo M; Cardali SM; Germanò A; Cingarlini S; Ghimenton C; Scarpa A
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31480372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
    Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
    Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
    Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
    Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
    Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
    Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
    Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.
    Cho YA; Kim D; Lee B; Shim JH; Suh YL
    J Neurooncol; 2021 May; 153(1):43-53. PubMed ID: 33864561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma.
    Richardson TE; Yokoda RT; Rashidipour O; Vij M; Snuderl M; Brem S; Hatanpaa KJ; McBrayer SK; Abdullah KG; Umphlett M; Walker JM; Tsankova NM
    Neurooncol Adv; 2023; 5(1):vdad085. PubMed ID: 37554222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
    Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
    J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme.
    Martinez R; Schackert HK; Appelt H; Plaschke J; Baretton G; Schackert G
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):87-93. PubMed ID: 15672285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative transcriptome analysis identified a BMP signaling pathway-regulated lncRNA AC068643.1 in IDH mutant and wild-type glioblastomas.
    Huang GH; Pei YC; Yang L; Mou KJ; Tang JH; Xiang Y; Liu J; Lv SQ
    Oncol Lett; 2020 Jul; 20(1):75-84. PubMed ID: 32565936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
    Ho WM; Chen CY; Chiang TW; Chuang TJ
    Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma.
    Poon CC; Gordon PMK; Liu K; Yang R; Sarkar S; Mirzaei R; Ahmad ST; Hughes ML; Yong VW; Kelly JJP
    Oncotarget; 2019 May; 10(33):3129-3143. PubMed ID: 31139325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
    Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
    Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients.
    Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U
    J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms associated with chromosomal and microsatellite instability in sporadic glioblastoma multiforme.
    Martinez R; Schackert HK; Plaschke J; Baretton G; Appelt H; Schackert G
    Oncology; 2004; 66(5):395-403. PubMed ID: 15331927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.